Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials
2017 ◽
Vol 32
(1)
◽
pp. 68-72
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2016 ◽
Vol 34
(15_suppl)
◽
pp. e18209-e18209
2016 ◽
Vol 75
(6)
◽
pp. 1162-1170.e3
◽
Keyword(s):
2017 ◽
Vol 76
(6)
◽
pp. AB150
Keyword(s):
2011 ◽
Vol 25
(7)
◽
pp. 851-857
◽
Keyword(s):
Keyword(s):
2013 ◽
Vol 28
(6)
◽
pp. 790-798
◽
Keyword(s):